Ustekinumab NCT07529236 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Recruiting

Recruitment status

40

Planned enrollment

2027-10-01

Primary-completion proxy

Executive view

NCT07529236 evaluates Ustekinumab in Psoriasis. The disclosed sponsor is Centre Hospitalier Universitaire de Nice, the design is Interventional, and the geographic footprint is France. The first listed primary endpoint is Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6), assessed over at baseline Month 0.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07529236 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Psoriasis landscape. Drug & Asset MCP drug_fetch was queried for Ustekinumab, while Company & Deal Intelligence MCP organization_fetch was queried for Centre Hospitalier Universitaire de Nice.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07529236	Ustekinumab	Not Applicable / Recruiting	Centre Hospitalier Universitaire de Nice	France	Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinum… at baseline Month 0	2027-10-01
NCT07581418	Tofacitinib Citrate	Not Applicable / Not yet recruiting	Sponsor not reported	Geography not reported	Change in Psoriasis Area and Severity Index (PASI) score 8 weeks	2026-12-01
ISRCTN91905052	Ixekizumab	Not Applicable / Recruiting	Guangdong Hospital of Traditional Chinese Medicine	China	Primary endpoint not reported Time frame not reported	2028-12-31
CTRI/2026/04/109640	Apremilast	Not Applicable / Not Yet Recruiting	Sponsor not reported	India		Timing not reported
NCT07546214	Tapinarof	Phase 1 / Completed	Sun Pharmaceutical Industries Ltd.	United States	Demonstration in Therapeutic Equivalence & Safety of the Investigational Product Baseline to Week 12	2026-03-18

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07529236 is a Not Applicable, recruiting study with 40 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6)” over “at baseline Month 0.” The retrieved endpoint description is: Severity scores for Crohn disease (PCDAI: The Pediatric Crohn's Disease Activity Index 0 to 100).

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 40 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Psoriasis. These records do not establish direct evidence for NCT07529236 unless the registration number matches.

Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study

Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41769731/

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis

Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607

Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase…

Phase 3; n=502; Adverse Event: nasopharyngitis = The most common treatment-emergent adverse events were upper respiratory tract infections and nasopharyngitis. Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42372782/

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Ustekinumab is indexed as Monoclonal antibody with IL-12p40 biology and a global stage of Approved. The asset profile lists Janssen Biotech, Inc. as an originator or developer.

Centre Hospitalier Universitaire de Nice is indexed in France with the website http://www.chu-nice.fr. Chu de Nice is a public health institution that provides healthcare services, pharmaceutical research, medical and paramedical training, The record lists 1 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Ustekinumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07529236
Protocol source: https://clinicaltrials.gov/study/NCT07529236
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Ustekinumab in Psoriasis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6) and 2027-10-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP